This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2011 May 24:342:d2758.

doi: 10.1136/bmj.d2758.

Duration of anticoagulation for venous thromboembolism

Saskia Middeldorp

PMID: 21610039
DOI: 10.1136/bmj.d2758

Editorial

Duration of anticoagulation for venous thromboembolism

Saskia Middeldorp. BMJ. 2011.

. 2011 May 24:342:d2758.

doi: 10.1136/bmj.d2758.

Author

Saskia Middeldorp

PMID: 21610039
DOI: 10.1136/bmj.d2758

No abstract available

PubMed Disclaimer

Comment on

Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials.
Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, Hirsh J, Kearon C. Boutitie F, et al. BMJ. 2011 May 24;342:d3036. doi: 10.1136/bmj.d3036. BMJ. 2011. PMID: 21610040 Free PMC article.

Similar articles

[Optimum duration of anticoagulant treatment after an episode of venous thromboembolism].
Couturaud F, Kearon C. Couturaud F, et al. Rev Pneumol Clin. 2008 Dec;64(6):305-15. doi: 10.1016/j.pneumo.2008.09.007. Epub 2008 Nov 18. Rev Pneumol Clin. 2008. PMID: 19084210 Review. French.
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events.
McNally MA. McNally MA. J Bone Joint Surg Br. 2007 Oct;89(10):1409; author reply 1409-10. doi: 10.1302/0301-620X.89B10.20325. J Bone Joint Surg Br. 2007. PMID: 17957087 No abstract available.
Extended therapy for primary and secondary prevention of venous thromboembolism.
Conway SE, Marcy TR. Conway SE, et al. J Pharm Pract. 2010 Aug;23(4):313-23. doi: 10.1177/0897190010366930. Epub 2010 May 7. J Pharm Pract. 2010. PMID: 21507831 Review.
Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities.
Taliani MR, Becattini C, Agnelli G, Prandoni P, Moia M, Bazzan M, Salvi R, Ageno W, Guazzaloca G, Imberti D, Silingardi M, Poggio R; Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Taliani MR, et al. Thromb Haemost. 2009 Mar;101(3):596-8. Thromb Haemost. 2009. PMID: 19277429 No abstract available.
Warfarin or not.
Oliver M. Oliver M. J R Coll Physicians Edinb. 2010 Dec;40(4):379; author reply 379-80. doi: 10.4997/JRCPE.2010.411. J R Coll Physicians Edinb. 2010. PMID: 21132153 No abstract available.

See all similar articles

Cited by

Sex matters: Practice 5P's when treating young women with venous thromboembolism.
Bistervels IM, Scheres LJJ, Hamulyák EN, Middeldorp S. Bistervels IM, et al. J Thromb Haemost. 2019 Sep;17(9):1417-1429. doi: 10.1111/jth.14549. Epub 2019 Jul 23. J Thromb Haemost. 2019. PMID: 31220399 Free PMC article. Review.
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.
Middeldorp S, Prins MH, Hutten BA. Middeldorp S, et al. Cochrane Database Syst Rev. 2014 Aug 5;2014(8):CD001367. doi: 10.1002/14651858.CD001367.pub3. Cochrane Database Syst Rev. 2014. PMID: 25092359 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information